Pipeline updates are highly awaited events in the
pharma/biotech sector as they play an important role in deciding
whether or not to invest in a particular company. Pipelines are
of prime importance as far as pharma/biotech companies are
concerned. These companies spend a significant amount in
advancing their pipelines.
Avanir Pharmaceuticals, Inc.
) pipeline looks promising with candidates like AVP-825, AVP-786
and Nuedexta (label expansion). Recently, Avanir submitted a New
Drug Application (NDA) to the U.S. Food and Drug Administration
(FDA) for its migraine candidate, AVP-825.
AVP-825 is being developed using OptiNose's novel Breath
Powered intranasal delivery system, which includes low dosages of
) Imitrex for the treatment of acute migraine.
The NDA was filed on the basis of a pivotal phase III trial on
AVP-825 and a phase II trial along with two pharmacokinetic
We note that Avanir joined forces with OptiNose for the
development and commercialization of AVP-825 for the treatment of
acute migraine on Jul 2, 2013.
Avanir's sole marketed product Nuedexta is expected to grow
around 13% sequentially to $31.3 million in the first quarter of
fiscal 2014 (year ending in Sep 2014). The approval of AVP-825
will reduce Avanir's dependence on a solitary product. Once
approved, AVP-825 will be the first and only fast-acting,
dry-powder intranasal form of Imitrex.
Avanir currently carries a Zacks Rank #3 (Hold). Some
better-ranked players in the pharma industry include
). Both the stocks carry a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
AVANIR PHARM (AVNR): Free Stock Analysis
ENDOCYTE INC (ECYT): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
To read this article on Zacks.com click here.